Daptomycin, sold under the brand name Cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.Daptomycin was removed from the World Health Organizations List of Essential Medicines in 2019. The World Health Organization classifies daptomycin as critically important for human medicine. Medical uses
In the United States, daptomycin is indicated for use in adults for skin and skin structure infections caused by Gram-positive infections, S. aureus bacteraemia, and right-sided S. aureus endocarditis. It binds avidly to pulmonary surfactant, so cannot be used in the treatment of pneumonia. There seems to be a difference in working daptomycin on hematogenous pneumonia. Adverse effects
Common adverse drug reactions associated with daptomycin therapy include:
Cardiovascular: low blood pressure, high blood pressure, swelling
Central nervous system: insomnia
Dermatological: rash
Gastrointestinal: diarrhea,  abdominal pain
Hematological: eosinophilia
Respiratory: dyspnea
Other: injection site reactions, fever, hypersensitivityLess common, but serious adverse events reported in the literature include

Hepatotoxicity: elevated transaminases
Nephrotoxicity: acute kidney injury from rhabdomyolysisAlso, myopathy and rhabdomyolysis have been reported in patients simultaneously taking statins, but whether this is due entirely to the statin or whether daptomycin potentiates this effect is unknown. Due to the limited data available, the manufacturer recommends that statins be temporarily discontinued while the patient is receiving daptomycin therapy. Creatine kinase levels are usually checked regularly while individuals undergo daptomycin therapy. In July 2010, the FDA issued a warning that daptomycin could cause life-threatening eosinophilic pneumonia. The FDA said it had identified seven confirmed cases of eosinophilic pneumonia between 2004 and 2010 and an additional 36 possible cases.
Drospirenone/estetrol, sold under the brand name Nextstellis among others, is a fixed-dose combination medication containing drospirenone, a progestin, and estetrol, an estrogen, which is used as a combined birth control pill for the prevention of pregnancy in women. It is taken by mouth.It was approved for medical use in Canada in March 2021, and in the United States in April 2021. Medical uses
Drospirenone/estetrol is used as a combined birth control pill to prevent pregnancy in women. Side effects
Estetrol-containing birth control pills, similarly to estradiol-containing birth control pills, may have a lower risk of venous thromboembolism (VTE) than ethinylestradiol-containing birth control pills based on studies of coagulation. However, it is likely that another decade will be required before post-marketing epidemiological studies of VTE incidence with these birth control pills are completed and able to confirm this. Pharmacology
Pharmacodynamics
Drospirenone/estetrol has a much lower impact on liver protein synthesis, including of sex hormone-binding globulin, angiotensinogen, and coagulation factors, than does ethinylestradiol/drospirenone. Society and culture
Legal status
Drospirenone/estetrol is approved for the use of hormonal contraception in the European Union, the United States, and Canada. Brand names
Drospirenone/estetrol in sold under the brand names Nexstellis, Drovelis, and Lydisilka. See also
Birth control pill formulations
List of combined sex-hormonal preparations § Estrogens and progestogens

References
External links
"Drospirenone". Drug Information Portal. U.S. National Library of Medicine. "Estetrol". Drug Information Portal. U.S. National Library of Medicine.